Prudential Financial Inc. continued to hold its stake in China Biologic Products, Inc. (NASDAQ:CBPO) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,280 shares of the biopharmaceutical company’s stock at the close of the 2nd quarter. Prudential Financial Inc.’s holdings in China Biologic Products were worth $484,000 at the end of the most recent reporting period.

Several other institutional investors have also recently modified their holdings of CBPO. FMR LLC raised its stake in China Biologic Products by 27.5% during the 1st quarter. FMR LLC now owns 1,880,549 shares of the biopharmaceutical company’s stock valued at $188,300,000 after purchasing an additional 406,105 shares during the last quarter. BlackRock Inc. raised its stake in China Biologic Products by 694.1% during the 1st quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after purchasing an additional 1,318,183 shares during the last quarter. Hermes Investment Management Ltd. raised its stake in China Biologic Products by 3.2% during the 2nd quarter. Hermes Investment Management Ltd. now owns 651,117 shares of the biopharmaceutical company’s stock valued at $73,641,000 after purchasing an additional 19,893 shares during the last quarter. Bank of New York Mellon Corp raised its stake in China Biologic Products by 4.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 586,459 shares of the biopharmaceutical company’s stock valued at $66,328,000 after purchasing an additional 22,932 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new position in China Biologic Products during the 1st quarter valued at $27,324,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

Several equities analysts recently commented on CBPO shares. Jefferies Group LLC reiterated a “buy” rating on shares of China Biologic Products in a research note on Friday, August 4th. Zacks Investment Research upgraded shares of China Biologic Products from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Finally, BidaskClub cut shares of China Biologic Products from a “hold” rating to a “sell” rating in a research note on Sunday, July 16th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $137.50.

TRADEMARK VIOLATION WARNING: “Prudential Financial Inc. Has $484,000 Holdings in China Biologic Products, Inc. (CBPO)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/10/11/prudential-financial-inc-has-484000-holdings-in-china-biologic-products-inc-cbpo.html.

China Biologic Products, Inc. (NASDAQ:CBPO) opened at 97.45 on Wednesday. China Biologic Products, Inc. has a 1-year low of $88.25 and a 1-year high of $125.99. The company’s 50-day moving average is $93.59 and its 200 day moving average is $103.42. The firm has a market capitalization of $2.65 billion, a PE ratio of 25.36 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The business had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. During the same quarter last year, the firm posted $1.26 EPS. The company’s quarterly revenue was down 2.3% on a year-over-year basis. On average, equities analysts expect that China Biologic Products, Inc. will post $4.95 EPS for the current fiscal year.

China Biologic Products Company Profile

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.